Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes

A method of delaying the onset of type I diabetes, and/or slowing the progression of type I diabetes, and/or reducing the severity of type I diabetes, and/or reversing type I diabetes in a mammal, said method comprising:

• coadministering to said mammal:
• a first compound comprising GABA, a GABA analogue, a GABA agonist, and/or a GABA or GABA agonist prodrug;
• and
• a second compound comprising a non-GABA therapeutic agent for the treatment of type I diabetes, and/or an anti-inflammatory compound, and/or a factor that stimulates a regulatory or immune response, and/or a GABAB receptor agonist;
• wherein said first compound and said second compound are administered in an amount sufficient to delay the onset of type I diabetes, and/or slow the progression of type I diabetes, and/or reduce the severity of type I diabetes, and/or reverse type I diabetes in said mammal.

A method of delaying the onset of hyperglycemia, and/or slowing the progression of hyperglycemia, and/or reducing the severity of hyperglycemia, and/or reversing hyperglycemia in a mammal, said method comprising:

• coadministering to said mammal:
• a first compound comprising GABA, a GABA analogue, a GABA agonist, and/or a GABA or GABA agonist prodrug;
• and
• a second compound comprising a non-GABA therapeutic agent for the treatment of type I diabetes, and/or an anti-inflammatory compound, and/or a factor that stimulates a regulatory or immune response, and/or a GABAB receptor agonist;
• wherein said first compound and said second compound are administered in an amount sufficient to delay the onset of hyperglycemia, and/or slow the progression of hyperglycemia, and/or reduce the severity of hyperglycemia, and/or reverse hyperglycemia in said mammal.

A method of promoting transplanted islet cell survival in a mammal having Type I diabetes or at risk for type I diabetes who is a recipient of transplanted islet cells, said method comprising:

• coadministering to said mammal:
• a first compound comprising GABA, a GABA analogue, a GABA agonist, and/or a GABA or GABA agonist prodrug;
• and
• a second compound comprising a non-GABA therapeutic agent for the treatment of type I diabetes, and/or an anti-inflammatory compound, and/or a factor that stimulates a regulatory or immune response, and/or a GABAB receptor agonist;
• wherein said first compound and said second compound are administered in an amount sufficient to promote transplanted islet cell survival in said mammal.

A method of delaying the onset of an immune response, and/or slowing the progression of an immune response, and/or reducing the severity of an immune response, and/or suppressing an immune response in a mammal, said method comprising:

• coadministering to said mammal:
• a first compound comprising GABA, a GABA analogue, a GABA agonist, a GABA or GABA agonist prodrug, and/or a GABA potentiator;
• and
• a second compound comprising a non-GABA therapeutic agent for the treatment of type I diabetes, and/or an anti-inflammatory compound, and/or a factor that stimulates a regulatory or immune response, and/or a GABAB receptor agonist;
• wherein said first compound and said second compound are administered in an amount sufficient to delay the onset of an immune response, and/or slow the progression of an immune response, and/or reduce the severity of an immune response, and/or suppress an immune response in said mammal.

A method of protecting beta-cells in a mammal from oxidative stress induced apoptosis said method comprising:

• coadministering to a mammal containing said β-cells:
• a first compound comprising GABA, a GABA analogue, a GABA agonist, a GABA or GABA agonist prodrug, and/or a GABA potentiator;
• and
• a second compound comprising a non-GABA therapeutic agent for the treatment of type I diabetes, and/or an anti-inflammatory compound, and/or a factor that stimulates a regulatory or immune response, and/or a GABAB receptor agonist;
• wherein said first compound and said second compound are administered in an amount sufficient to partially or fully protect said beta cells from oxidative stress induced apoptosis.

A first compound comprising GABA, a GABA analogue, a GABA agonist, and/or a GABA or GABA agonist prodrug;

• and a second compound comprising a non-GABA therapeutic agent for the treatment of type I diabetes, and/or an anti-inflammatory compound, and/or a factor that stimulates a regulatory or immune response, and/or a GABAB receptor agonist for use in conjunction with each other to:
• delay the onset of type I diabetes, and/or slow the progression of type I diabetes, and/or reduce the severity of type I diabetes, and/or reverse type I diabetes in a mammal;
• and/or
• to promote transplanted islet cell survival in a mammal;
• and/or
• to delay the onset of hyperglycemia, and/or to slow the progression of hyperglycemia, and/or to reduce the severity of hyperglycemia, and/or to reverse hyperglycemia in a mammal;
• and/or
• to promote transplanted islet cell survival in a mammal having type I diabetes or at risk for type I diabetes who is a recipient of transplanted islet cells;
• and/or
• to delay the onset of an immune response, and/or slow the progression of an immune response, and/or reduce the severity of an immune response, and/or suppress an immune response in a mammal;
• and/or
• to protect beta-cells in a mammal from oxidative stress induced apoptosis.